Phaseline

Targets › CHRM5

CHRM5 (Muscarinic acetylcholine receptor M5): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Respiratory, Ophthalmology; next expected readout Oct 2027.

The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover. (UniProt, P08912)

Open in Phaseline: the race on CHRM5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstraZenecaGlycopyrronium
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor inhibitor
CHRM3, CHRM1, CHRM4, CHRM2, CHRM5Phase 2AsthmaMay 2029
GenSight BiologicsGS030-DP
Recombinant adeno-associated viral vector (rAAV2.7m8) delivering ChrimsonR-tdTomato gene f
CHRM5Phase 1Non-syndromic Retinitis PigmentosaOct 2027

Conditions

Asthma (1) Non-syndromic Retinitis Pigmentosa (1)

Modalities

other (1)

Companies

AstraZeneca (1) GenSight Biologics (1)

Related targets

CHRM3 (1) CHRM1 (1) CHRM4 (1) CHRM2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.